< 生产厂家 价格 >

兰索拉唑

兰索拉唑用途

Lansoprazole(AG-1749)是质子泵抑制剂,能抑制胃酸生成。
点击显示

兰索拉唑名称

[ CAS 号 ]:
103577-45-3

[ 中文名 ]:
兰索拉唑

[ 英文名 ]:
Lansoprazole

[中文别名 ]:

[英文别名 ]:

兰索拉唑生物活性

[ 描述 ]:

Lansoprazole(AG-1749)是质子泵抑制剂,能抑制胃酸生成。

[ 相关类别 ]:

信号通路 >> 跨膜转运 >> 质子泵
研究领域 >> 炎症/免疫

[参考文献]

[1]. Kokufu, T., et al., Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol, 1995. 48(5): p. 391-5.

[2]. Lai, K.C., et al., Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med, 2002. 346(26): p. 2033-8.

[3]. Iwahi, T., et al., Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother, 1991. 35(3): p. 490-6.


[相关活性小分子]

巴佛洛霉素A1 | 奥美拉唑 | 富马酸沃诺拉赞 | 吡啶硫酮锌 | 右旋兰索拉唑 | 艾普拉唑 | Linaprazan | Soraprazan | 巴马司特 | 耐信(埃索美拉唑镁) | 埃索美拉唑镁(三水) | 诃子林鞣酸 | 吡考拉唑 | SKF96067 | Pumaprazole

兰索拉唑物理化学性质

[ 密度 ]:
1.5±0.1 g/cm3

[ 沸点 ]:
555.8±60.0 °C at 760 mmHg

[ 熔点 ]:
178-182°C dec.

[ 分子式 ]:
C16H14F3N3O2S

[ 分子量 ]:
369.362

[ 闪点 ]:
289.9±32.9 °C

[ 精确质量 ]:
369.075867

[ PSA ]:
87.08000

[ LogP ]:
2.76

[ 外观性状 ]:
白色结晶粉末

[ 蒸汽压 ]:
0.0±1.5 mmHg at 25°C

[ 折射率 ]:
1.635

[ 储存条件 ]:
2-8°C

兰索拉唑MSDS

详细MSDS(安全技术说明书)

兰索拉唑毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :
DD9487500
CHEMICAL NAME :
1H-Benzimidazole, 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)m ethyl)sulfinyl)-
CAS REGISTRY NUMBER :
103577-45-3
LAST UPDATED :
199703
DATA ITEMS CITED :
11
MOLECULAR FORMULA :
C16-H14-F3-N3-O2-S
MOLECULAR WEIGHT :
369.39

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>5 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 18(Suppl 10),S2657,199
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
5 gm/kg
TOXIC EFFECTS :
Behavioral - changes in motor activity (specific assay) Behavioral - muscle weakness Lungs, Thorax, or Respiration - respiratory depression
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 18(Suppl 10),S2657,199
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>5 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 18(Suppl 10),S2657,199
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
58 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - ataxia Lungs, Thorax, or Respiration - respiratory depression
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 24,905,1996
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>5 gm/kg
TOXIC EFFECTS :
Kidney, Ureter, Bladder - other changes
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 18(Suppl 10),S2657,199
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>5 gm/kg
TOXIC EFFECTS :
Behavioral - changes in motor activity (specific assay) Behavioral - muscle weakness Kidney, Ureter, Bladder - other changes
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 18(Suppl 10),S2657,199
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>5 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 18(Suppl 10),S2657,199
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
75 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - respiratory depression
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 24,905,1996 ** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
5460 mg/kg/13W-I
TOXIC EFFECTS :
Endocrine - changes in thymus weight Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 24,913,1996 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
3600 mg/kg
SEX/DURATION :
female 6-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 18(Suppl 10),S2773,199
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
390 mg/kg
SEX/DURATION :
female 6-18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 18(Suppl 10),S2773,199
点击显示

兰索拉唑安全信息

[ 符号 ]:

GHS07

[ 信号词 ]:
Warning

[ 危害声明 ]:
H315-H319-H335

[ 警示性声明 ]:
P305 + P351 + P338

[ 个人防护装备 ]:
dust mask type N95 (US);Eyeshields;Gloves

[ 危害码 (欧洲) ]:
Xi:Irritant

[ 风险声明 (欧洲) ]:
R36/37/38

[ 安全声明 (欧洲) ]:
S26-S36

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
2

[ RTECS号 ]:
DD9487500

[ 海关编码 ]:
2933990090

兰索拉唑合成路线

详细合成路线

兰索拉唑上下游产品

兰索拉唑上游产品

兰索拉唑下游产品

兰索拉唑制备

往2，3-二甲基吡啶中加入冰乙酸和部分30%双氧水，加热后再补加剩下的双氧水。反应结束后，减压蒸出溶剂，得化合物(I)。将其缓慢加入混酸中，加热，得硝化产物(Ⅱ)。
三氟乙醇的溶液在碱性条件下反应数小时，滴入硝化产物(Ⅱ)，加热得到取代产物(Ⅲ)。
往取代产物(Ⅲ)中，滴人乙酸酐和浓硫酸，加热。减压抽去溶剂，残物加入甲醇、水和氢氧化钠配成的溶液，调至碱性，室温反应。得化合物(Ⅳ)。
化合物(Ⅳ)溶于氯仿，滴人二氯亚砜，回流。减压蒸出溶剂，加入甲醇待用。另外加入2-巯基苯并咪唑和甲醇钠的甲醇溶液，回流。降温后，滴入待用的甲醇溶液，回流得化合物(V)。
化合物(V)溶于二氯甲烷，缓慢滴入双氧水、五氧化二钒和叔丁醇所成的溶液。反应结束后，加入0.5%硫代硫酸钠溶液，剧烈搅拌。处理后得兰索拉唑。
点击显示

兰索拉唑海关

[ 海关编码 ]: 2933990090

[ 中文概述 ]:
2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期

[ Summary ]:
2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

兰索拉唑文献

Solvent-free melting techniques for the preparation of lipid-based solid oral formulations.

Pharm. Res. 32(5) , 1519-45, (2015)

Lipid excipients are applied for numerous purposes such as taste masking, controlled release, improvement of swallowability and moisture protection. Several melting techniques have evolved in the last...

Preventing metachronous gastric lesions after endoscopic submucosal dissection through Helicobacter pylori eradication.

J. Gastroenterol. Hepatol. 30(1) , 75-81, (2014)

Metachronous recurrence often occurs after endoscopic submucosal dissection for early gastric cancer, and a method for preventing recurrence is unknown. We aimed to identify risk factors for metachron...

Seco-taondiol, an unusual meroterpenoid from the Chilean seaweed Stypopodium flabelliforme and its gastroprotective effect in mouse model.

Mar. Drugs 13 , 1726-38, (2015)

Ten known meroterpenoids and the new meroterpenoid 7 were isolated from the Chilean seaweed Stypopodium flabelliforme as their acetylated derivatives. Furthermore, the known metabolite taondiol has be...


更多文献

相关药品：

推荐生产厂家/供应商：

公司名：上海化源生化科技有限公司

区域：上海市普陀区

价格：

联系人：徐经理

产品详情：Lansoprazole

公司名：上海吉至生化科技有限公司

区域：上海市奉贤区

价格：
￥178.0/5g ￥598.0/25g

联系人：刘佳

产品详情：兰索拉唑

公司名：上海源溪生物科技有限公司

区域：上海市浦东新区

价格：
￥需询单/1g

联系人：赖经理

产品详情：Lansoprazole

公司名：上海脉铂医药科技有限公司

区域：上海市嘉定区

价格：
￥649.0/1g ￥589.0/1g ￥需询单/1g ￥需询单/1g

联系人：李先生

产品详情：Lansoprazole

公司名：上海阿拉丁生化科技股份有限公司

区域：上海市浦东新区

价格：
￥59.9/1g ￥29.9/250mg ￥499.9/1ml ￥1295.9/100g

联系人：阿拉丁

产品详情：兰索拉唑

查看所有供应商请点击：

兰索拉唑供应商

相关化合物

本网页内容来自不同专业数据源，如对内容有疑义，欢迎联系service1@chemsrc.com。

【兰索拉唑】化源网提供兰索拉唑CAS号103577-45-3，兰索拉唑MSDS及其说明、性质、英文名、生产厂家、作用/用途、分子量、密度、沸点、熔点、结构式等。CAS号查询兰索拉唑上化源网，专业又轻松。>>电脑版：兰索拉唑

标题：兰索拉唑_MSDS_用途_密度_兰索拉唑CAS号【103577-45-3】_化源网 地址：https://m.chemsrc.com/mip/cas/103577-45-3_1084289.html